Continuous renal replacement therapy and extended indications.
Claudio RoncoThiago ReisPublished in: Seminars in dialysis (2021)
Extracorporeal blood purification (EBP) techniques provide support for critically ill patients with single or multiple organ dysfunction. Continuous renal replacement therapy (CRRT) is the modality of choice for kidney support for those patients and orchestrates the interactions between the different artificial organ support systems. Intensive care teams should be familiar with the concept of sequential extracorporeal therapy and plan on how to incorporate new treatment modalities into their daily practices. Importantly, scientific evidence should guide the decision-making process at the bedside and provide robust arguments to justify the costs of implementing new EBP treatments. In this narrative review, we explore the extended indications for CRRT as an adjunctive treatment to provide support for the heart, lung, liver, and immune system. We detail practicalities on how to run the treatments and how to tackle the most frequent complications regarding each of the therapies, whether applied alone or integrated. The physicochemical processes and technologies involved at the molecular level encompassing the interactions between the molecules, membranes, and resins are spotlighted. A clinical case will illustrate the timing for the initiation, maintenance, and discontinuation of EBP techniques.
Keyphrases
- decision making
- end stage renal disease
- acute kidney injury
- chronic kidney disease
- ejection fraction
- healthcare
- heart failure
- newly diagnosed
- primary care
- oxidative stress
- peritoneal dialysis
- stem cells
- physical activity
- risk factors
- combination therapy
- quality improvement
- single molecule
- bone marrow
- patient reported outcomes
- recombinant human